Our findings provide strong rationale that the state of myeloid cells significantly influences I/O responses and highlights the need for combining KRAS cancer-targeted therapy with myeloid activating I/O to enhance and prolong antitumor effects. The gene discussed is KRAS; the disease is cancer.